Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU014813 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| SU014813 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SU014813 | DRUG | 100 mg capsule/day for 6 cycle of 21 days |
Inclusion Criteria: * Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent. * Must have received prior treatment with an anthracycline and a taxane either concurrently or se...
SU014813 is an investigational small molecule being studied for the treatment of breast cancer and other solid tumors. It was evaluated in patients with metastatic breast cancer and in patients with advanced solid malignancies. The drug is being developed by Pfizer, Inc. and is currently in Phase 2 clinical development.
SU014813 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in the oncology therapeutic area, and it has not been approved by regulatory authorities.
SU014813 is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with metastatic breast cancer and one Phase 1 trial in patients with advanced solid tumors. The drug remains investigational and has not received regulatory approval.
SU014813 has been studied in two completed clinical trials. NCT00322517 was a Phase 2 study of the efficacy and safety of SU-014813 in patients with metastatic breast cancer, enrolling 90 female patients. NCT00982267 was a Phase 1 trial of SU14813 in patients with advanced solid malignancies, enrolling 77 patients.
Yes, SU014813 is also known as SU-014813 and SU14813. These names refer to the same investigational drug developed by Pfizer. The Phase 2 trial used the name SU-014813, while the Phase 1 trial used the name SU14813.